Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00166504
Status:
COMPLETED
Last Update Posted:
2024-05-22
First Post:
2005-09-09
Brief Title:
Ezetimibe Plus Simvastatin Versus Atorvastatin Comparative Study 0653A-092COMPLETED
Sponsor:
Organon and Co
Organization:
Organon and Co
Study Overview
Official Title:
A Multicenter Randomized Open-label Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe Simvastatin Versus Atorvastatin in Patients With Primary Hypercholesterolemia
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an efficacy and safety study of Vytorin ezetimibe simvastatin compared to atorvastatin ezetimibesimvastatin at week 6 in primary hypercholesterolemia patients in Korea The primary hypothesis being tested is that daily administration of Vytorin will result in a greater reduction of low density lipoprotein cholesterol LDL-C concentration from baseline after 6 weeks treatment compared to atorvastatin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_070 | None | None | None |
| MK0653A-092 | None | None | None |